Non-Small-Cell Lung Cancer
Conditions
Interventions
Icotinib combination chemotherapy group:Chemotherapy (on day 1 of each 3 week cycle) in combination with Icotinib (125 mg po three times a day on days 2-15 of each 3 week cycle) for 4 cycles
then continue to receive Icotinib 125 mg po three times a day daily until progression
Icotinib alone threapy group:Receive Icotinib 125 mg po three times a day daily until progression
Sponsors
Shandong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21); 2. Adult patients, older than 18 years of age; 3. Advanced (stage IIIB/IV) non-small-cell lung cancer; 4. Although stage I-IIIA, have contraindications to surgery; 5. ECOG Performance Status 0 or 1 or 2 or 3; 6. All subjects or their guardians must sign an informed consent before entering the trial.
Exclusion criteria
Exclusion criteria: 1. Wild-type EGFR; 2. Are allergic to Icotinib, pemetrexed, docetaxel or carboplatin or with intolerance; 3. Prior chemotherapy or systemic anti-tumor therapy after advanced disease; 4. Unstable systemic disease; 5. Brain metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Disease control rate (DCR);Overall survival (OS); | — |
Countries
China
Contacts
Public ContactLi Yu
Outcome results
None listed